Payment overview · 2025
General Payments
$425.06
27 reported records · 9 companies
Healthcare provider profile · identity verified
Carl D. Pate, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BEULAVILLE, NC · NPI 1346323375
Verified facts
What the public records show
CMS Open Payments records show Carl D. Pate, M.D. received $425.06 in general payments during 2025 across 27 reported records.
Lilly USA, LLC accounted for 33.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $142.73 | 33.6% | 11 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $114.38 | 26.9% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.69 | 8.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.79 | 8.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.93 | 7.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.77 | 4.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.73 | 3.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.39 | 3.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.65 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $425.06 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $114.38 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $107.56 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $107.56 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.69 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $35.17 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.93 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 440 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 319 | 82 |
| Omeprazole | Omeprazole | 286 | 68 |
| Losartan Potassium | Losartan Potassium | 279 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 265 | 60 |
| Furosemide | Furosemide | 245 | 64 |
| Potassium Chloride | Potassium Chloride | 226 | 46 |
| Lisinopril | Lisinopril | 219 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 217 | 50 |
| Gabapentin | Gabapentin | 214 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 212 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 51 |
| Meloxicam | Meloxicam | 172 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 166 | 28 |
| Eliquis | Apixaban | 165 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 154 | 35 |
| Alprazolam | Alprazolam | 152 | 32 |
| Montelukast Sodium | Montelukast Sodium | 144 | 31 |
| Trazodone Hcl | Trazodone Hcl | 135 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 52 |
| Famotidine | Famotidine | 109 | 27 |
| Tramadol Hcl | Tramadol Hcl | 107 | 25 |
| Metformin Hcl | Metformin Hcl | 99 | 26 |
| Simvastatin | Simvastatin | 97 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 25 |
| Jardiance | Empagliflozin | 90 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 18 |
| Clonazepam | Clonazepam | 83 | 11 |
| Carvedilol | Carvedilol | 79 | 23 |
| Prednisone | Prednisone | 75 | 47 |
| Sertraline Hcl | Sertraline Hcl | 75 | 17 |
| Metformin Hcl Er | Metformin Hcl | 71 | 20 |
| Ozempic | Semaglutide | 69 | suppressed |
| Atenolol | Atenolol | 66 | 13 |
| Myrbetriq | Mirabegron | 61 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 14 |
| Pregabalin | Pregabalin | 59 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 13 |
| Ezetimibe | Ezetimibe | 56 | 12 |
| Methylprednisolone | Methylprednisolone | 56 | 46 |
| Oxycodone Hcl | Oxycodone Hcl | 55 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | suppressed |
| Allopurinol | Allopurinol | 47 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 16 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Finasteride | Finasteride | 44 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 16 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Bumetanide | Bumetanide | 36 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 21 |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 25 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 23 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Oxycontin | Oxycodone Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 16 |
| Diazepam | Diazepam | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Triazolam | Triazolam | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $425.06 · 27 records | Lilly USA, LLC | AREXVY, BREZTRI, CAPVAXIVE, JARDIANCE, Korlym, MOUNJARO, ROTATEQ, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VAXELIS, VAXNEUVANCE, VRAYLAR, Veozah, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error